Browsing by Author "Yurtsever F."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Obsessive-compulsive disorder in a dermatology outpatient clinic
    (2005) Demet M.M.; Deveci A.; Taskin E.O.; Ermertcan A.T.; Yurtsever F.; Deniz F.; Bayraktar D.; Ozturkcan S.
    Objective: The aims of present study were to (a) to determine the prevalence of obsessive-compulsive disorder (OCD) in dermatological patients, (b) to determine the possible relationship between dermatological lesions and OCD and (c) to determine the clinical and phenomenological features of the OCD subgroup. Method: The sample consisted of 166 out of 250 consecutively presenting dermatological patients who agreed to participate in the study. The subjects were assessed with the Structured Clinical Interview for DSM-IV Turkish Version (SCID-I) and also completed the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Results: Of the whole sample, 41 (24.7%) met DSM-IV criteria for OCD. Only 14.6% of them had previously been diagnosed as OCD. The mean score of Y-BOCS in the OCD group was 17.05±9.75. The most common obsessions were contamination (61%) and pathologic doubt (53.7%), while washing (61%) and checking (51.2%) were the most frequent compulsions. Those suffering from diseases of sebaceous glands were the only group that showed a significant difference between the OCD and non-OCD group. Conclusion: There is a high prevalence of OCD in dermatological patients, although the nature of the relationship between OCD and dermatology has not previously been ascertained. Genetic-based studies and future researches focused on individual anxiety, and sensitivity may provide information that better explains this relationship. © 2005 Elsevier Inc. All rights reserved.
  • No Thumbnail Available
    Item
    The effect of the family history of diabetes on glucose metabolism of the patients recieving atypical antipsychotics; [Atipik antipsikotik kullanan hastalarda ailede diyabet öykü sü olmasinin glukoz metabolizmasi üzerine olan etkisi]
    (2007) Yurtsever F.; Esen-Danaci A.; Taneli F.; Günay Ö.; Veznedaroǧlu B.
    Objective: Diabetes is observed 2-3 times more frequently in schizophrenic patients with comparison to the general population. Recently, many publications have reported diabetes related to atypical antipsychotics. Risk factors such as age, ethnicity, overweight, duration of obesity, physical activity, and family history of diabetes seem to help development of diabetes. This study aims to investigate how the glucose metabolism is affected from familial history of diabetes which is a risk factor for the disease. Method: Seventy patients who have a diagnosis of schizophrenia or other psychotic disorders and are treated with atypical antipsychotics for at least one year were recruited for the study. The patients were divided into two groups defined as those with or without a family history of diabetes. In order to evaluate the glucose metabolism fasting blood glucose, oral glucose tolerance, blood insuline, c-peptide, hemoglobine A1c, leptin and ghrelin levels were measured. Results: The results of the comparison of fasting blood glucose, oral glucose tolerance, blood insuline, c-peptide, hemoglobine A1c, leptin and ghrelin levels between two patient groups with and without family history of diabetesonly ghrelin levels were found to be statistically higher in the group of patients with a history of diabetes in their family; no other parameters have statistically significant differencesbetween two groups. Conclusion: Having a family history of diabetes may increase the probabality of disturbance in glucose metabolism of the patients receiving atypical antipsychotics. It would be reasonable to evaluate the risk factors prior to the treatment and routinely review the parameters required to evaluate the metabolic side effects in clinical follow-ups.
  • No Thumbnail Available
    Item
    Mechanism of diabetes related to atypical antipsychotics; [Atipik antipsikotiklere baǧli geliflen diyabetin mekanizmasi]
    (2007) Yurtsever F.; Esen-Danaci A.; Deveci A.
    New researches and case reports have revealed that diabetes incidence is higher in patients treated with new generation antipsychotics. The incidence of diabetes is 2-3 fold in schizophrenic patients compared to normal population. It is confuses that the use of new generation antipsychotics increases the risk of diabetes and cardiovascular diseases related to it. With the use of new generation antipsycotics onset age of diabetes went under 40 years in patients with schizophrenia. Even though the mechanism of diabetes caused by new generation antipsychotics is unclear some hypotheses include mechanisms related with dopamine receptor antagonism, increase in body weight, histamine 1 and 5-HT2A or 5-HT2C receptor antagonism, increase in serum leptin, insulin resistance and direct effects on pancreas. We reviewed the evidence regarding the diabetogenic effects of new generation antipsychotics and possible underlying mechanisms of this effect.
  • No Thumbnail Available
    Item
    Effects of second generation antipsychotics on leptin and ghrelin
    (2008) Esen-Danaci A.; Sarandöl A.; Taneli F.; Yurtsever F.; Özlen N.
    Background: Weight gain is a major side effect of antipsychotic treatment. Some atypical antipsychotic agents have profound effects on weight. Body weight is regulated by a complex system, including both peripheral and central factors. Two of the hormones that seem to play an important role in the regulation of food intake, energy metabolism, and body weight are leptin and ghrelin. Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby inducing weight loss. Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in meal initiation. In this present study it is aimed to compare the effects of five different atypical antipsychotic medications on leptin and ghrelin. Method: 112 patients who were treated either with clozapine (n = 20), olanzapine (n = 28), risperidone (n = 22), quetiapine (n = 20) or amisulpride (n = 22) as monotherapy for at least one year and age, gender, and body mass index (BMI) matched control group (n = 23) were assessed cross-sectionally. Ghrelin and leptin levels were measured with enzyme-immunoassay. Results: When fasting serum leptin levels were compared between groups, control group had the highest mean value (9.2 ± 6.7) and amisulpride group had the lowest mean value (3.7 ± 2.1) but still there was no statistically significant difference between six groups (F = 1993, p = 0.084). In the comparison of the mean values of fasting serum ghrelin levels there was a statistically significant difference between groups (F = 11,473, p = 0.00). In post-hoc analysis it was seen that the control group had the lowest ghrelin level (194.5 ± 86.8). Quetiapine treated group (378.1 ± 260.4) had similar fasting serum ghrelin levels to control group. All the other antipsychotic treatment groups had significantly higher levels of fasting serum ghrelin compared to control group, highest in amisulpride treated group (597.0 ± 150.0). Conclusion: The weight-gain side effect of atypical antipsychotics can be related with the orexigenic effect of elevated serum ghrelin rather than leptin deficit. Among the five widely used atypical antipsychotics quetiapine is the only one which does not elevate the ghrelin level. © 2008 Elsevier Inc. All rights reserved.